Strategic Acquisition Momentum Recent ownership shift under Altaris and planned integration with Minaris expands the combined cell therapy CDMO footprint, enabling cross-sell of development, testing, and manufacturing services to larger programs while ensuring business continuity during milestones.

End-to-End Platform Advanced Therapies offers integrated CTDMO capabilities across development, testing, and manufacturing for cell therapies, including established CAR-T platform development, enabling rapid program progression and greater predictability for clients.

Partnership Track Record Historical collaborations with Janssen and Wugen demonstrate a strong track record in co-development and manufacturing partnerships, indicating readiness to engage in new strategic alliances and multi-vendor programs.

Global Scale Opportunity The planned combination into a globally capable organization with Minaris positions the firm to offer scaled manufacturing across regions, reduce production costs, and shorten timelines for life-saving therapies.

Quality Edge In-house testing and release capabilities, biosafety processes, and recognized industry leadership strengthen the value proposition for clients seeking reliable, compliant manufacturing partners.